Halozyme Total Assets vs Short Long Term Debt Analysis
HALO Stock | USD 44.29 0.94 2.17% |
Halozyme Therapeutics financial indicator trend analysis is much more than just examining Halozyme Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Halozyme Therapeutics is a good investment. Please check the relationship between Halozyme Therapeutics Total Assets and its Short Long Term Debt accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.
Total Assets vs Short Long Term Debt
Total Assets vs Short Long Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Halozyme Therapeutics Total Assets account and Short Long Term Debt. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Halozyme Therapeutics' Total Assets and Short Long Term Debt is -0.12. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Short Long Term Debt in the same time period over historical financial statements of Halozyme Therapeutics, assuming nothing else is changed. The correlation between historical values of Halozyme Therapeutics' Total Assets and Short Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Halozyme Therapeutics are associated (or correlated) with its Short Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt has no effect on the direction of Total Assets i.e., Halozyme Therapeutics' Total Assets and Short Long Term Debt go up and down completely randomly.
Correlation Coefficient | -0.12 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Total Assets
Total assets refers to the total amount of Halozyme Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Halozyme Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Short Long Term Debt
The total of a company’s short-term and long-term borrowings.Most indicators from Halozyme Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Halozyme Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.At this time, Halozyme Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 1st of June 2024, Tax Provision is likely to grow to about 70.1 M, while Sales General And Administrative To Revenue is likely to drop 0.44.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 361.9M | 520.8M | 636.9M | 668.7M | Total Revenue | 443.3M | 660.1M | 829.3M | 870.7M |
Halozyme Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Halozyme Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Halozyme Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 565.9M | 579.9M | 1.1B | 1.8B | 1.7B | 1.8B | |
Other Current Liab | 55.6M | 20.5M | 24.4M | 96.5M | 100.7M | 105.7M | |
Total Current Liabilities | 85.6M | 421.4M | 117.1M | 130.8M | 112.5M | 67.5M | |
Total Stockholder Equity | 91.8M | 151.0M | 197.0M | 169.8M | 83.8M | 66.9M | |
Net Debt | 282.4M | 249.5M | 758.0M | 1.3B | 1.4B | 1.4B | |
Retained Earnings | (603.7M) | (474.6M) | (58.9M) | 143.2M | 90.6M | 95.1M | |
Cash | 120.2M | 147.7M | 118.7M | 234.2M | 118.4M | 81.7M | |
Cash And Short Term Investments | 421.3M | 368.0M | 740.9M | 362.8M | 336M | 196.9M | |
Common Stock Total Equity | 145K | 137K | 135K | 138K | 155.3K | 104.5K | |
Common Stock Shares Outstanding | 144.3M | 141.5M | 146.8M | 140.6M | 134.2M | 104.7M | |
Liabilities And Stockholders Equity | 565.9M | 579.9M | 1.1B | 1.8B | 1.7B | 1.8B | |
Other Stockholder Equity | 695.1M | 625.5M | 256.3M | 27.4M | 2.4M | 2.3M | |
Total Liab | 474.1M | 428.9M | 907.5M | 1.7B | 1.6B | 1.7B | |
Total Current Assets | 543.4M | 554.8M | 926.3M | 739.0M | 746.4M | 783.7M | |
Common Stock | 145K | 137K | 135K | 138K | 127K | 106.0K | |
Short Long Term Debt Total | 402.6M | 397.2M | 876.7M | 1.5B | 1.5B | 1.6B | |
Accounts Payable | 6.4M | 1.9M | 1.5M | 17.7M | 11.8M | 12.4M | |
Property Plant And Equipment Net | 10.9M | 10.6M | 8.8M | 75.6M | 74.9M | 78.7M | |
Non Current Assets Total | 22.4M | 25.2M | 178.1M | 1.1B | 986.8M | 1.0B | |
Non Currrent Assets Other | 11.1M | 14.1M | 13.9M | 26.3M | 17.8M | 9.0M | |
Other Assets | 11.6M | 14.6M | 169.3M | 71.2M | 81.9M | 86.0M | |
Inventory | 29.4M | 60.7M | 53.9M | 100.1M | 127.6M | 134.0M | |
Other Current Assets | 33.4M | 28.3M | 40.5M | 45.0M | 48.6M | 51.0M | |
Property Plant And Equipment Gross | 10.9M | 10.6M | 21.9M | 90.3M | 94.6M | 99.3M | |
Accumulated Other Comprehensive Income | 240K | 22K | (620K) | (922K) | (9.3M) | (8.8M) | |
Property Plant Equipment | 10.9M | 10.6M | 8.8M | 75.6M | 86.9M | 91.3M | |
Current Deferred Revenue | 4.2M | 4.0M | 1.7M | 3.2M | (32.2M) | (30.6M) | |
Net Receivables | 59.4M | 97.7M | 91.0M | 231.1M | 234.2M | 245.9M | |
Other Liab | 2.3M | 7.5M | 3.1M | 17.7M | 16.0M | 26.6M | |
Non Current Liabilities Total | 388.5M | 7.5M | 790.3M | 1.5B | 1.5B | 1.6B | |
Net Tangible Assets | 90.5M | 155.1M | 197.0M | (783.7M) | (705.3M) | (670.0M) | |
Long Term Debt | 34.9M | 383.0M | 787.3M | 1.5B | 1.5B | 1.6B | |
Retained Earnings Total Equity | (603.7M) | (474.6M) | (58.9M) | 143.2M | 164.7M | 172.9M | |
Short Term Investments | 301.1M | 220.3M | 622.2M | 128.6M | 217.6M | 203.8M | |
Capital Surpluse | 695.1M | 625.5M | 256.3M | 27.4M | 31.5M | 29.9M | |
Long Term Debt Total | 34.9M | 383.0M | 787.3M | 1.5B | 1.7B | 1.8B | |
Non Current Liabilities Other | 4.2M | 3.5M | 544K | 45.9M | 37.7M | 39.6M | |
Short Long Term Debt | 19.5M | 397.2M | 89.4M | 13.3M | 15.3M | 14.6M | |
Short Term Debt | 19.5M | 397.2M | 89.4M | 13.3M | 32.2M | 30.6M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Halozyme Stock analysis
When running Halozyme Therapeutics' price analysis, check to measure Halozyme Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Halozyme Therapeutics is operating at the current time. Most of Halozyme Therapeutics' value examination focuses on studying past and present price action to predict the probability of Halozyme Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Halozyme Therapeutics' price. Additionally, you may evaluate how the addition of Halozyme Therapeutics to your portfolios can decrease your overall portfolio volatility.
CEOs Directory Screen CEOs from public companies around the world | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
Is Halozyme Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.069 | Earnings Share 2.41 | Revenue Per Share 6.643 | Quarterly Revenue Growth 0.208 | Return On Assets 0.1348 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.